ANTHONY PAYNE
                                        607 Birchwood Court
                                        Jefferson, SD 57038
Home: 605.540.0442                    matpayne@cableone.net                        Cell: 712.574.0216


                                             SUMMARY

Accomplished Sales Professional with proven ability to drive territorial growth. A self-motivated
expeditor known for creating and implementing effective targeting strategies to maximize results with
high value customers. Additional strengths in making consultative sales presentations, providing
excellent customer service, and continued industry self education.


                                  PROFESSIONAL EXPERIENCE

GLAXOSMITHKLINE, Research Triangle Park, NC                                               2008 – 2010
Pharmaceutical Sales Representative
Promoted medications in a sales team environment to practicing physicians and mid-level providers
within an assigned territory that ensured the appropriate use of products to achieve the business
potential of the territory.
•       Ranked in the Top 10% Nationally for Lovaza 1st Quarter 2010 goal attainment by building
        relationships with medical providers and providing relevant information about the link
        between cardiovascular disease and product benefits.
•       Assigned to a dormant, under-performing territory in January 2009, developed and executed
        a sales strategy which transformed the territory to a ranking of Top 10% nationally in division
        portfolio attainment within a year.
•       First place rank regionally during the 4th Quarter of 2008 in Total Portfolio Achievement with
        a portfolio achievement of 257% of goal, executing on division plan of action in a newly
        developed territory after being retained by GlaxoSmithKline in April 2008.

RELIANT PHARMACEUTICALS, Liberty Corner, NJ                                               2001 – 2008
Pharmaceutical Sales Representative
Ethically promoted medications in a single member territory environment to practicing physicians
and mid-level providers in a variety of assigned territories that ensured the appropriate use of
promoted products to maximize profitability of the territories.
•       Developed and executed a plan of action that resulted in a 6th place rank nationally in Total
        Portfolio Achievement of the 90 sales professionals that were retained by GlaxoSmithKline
        after the purchase and merger of Reliant Pharmaceuticals.
•       Awarded additional territory in January 2007 that had been dormant for two years.
        Introduced Lovaza with a well defined and executed strategy that led to a Top 1% rank
        nationally in Total Prescription Growth in the Primary Care Division during the 4th Quarter
        over 3rd Quarter 2007 with 33.69% increase in sales.
•       Utilized national Dyna Circ CR branding strategy while incorporating personally customized
        execution of this strategy resulting in the Exceptional Sales Achievement in Hypertension
        Award in October 2006, and again in May 2007.
•       Followed regionally developed portfolio plan of action while maximizing features and benefits
        of portfolio products resulting in the Regional Sales Award for the 4th Quarter 2002 and
        again for the 2nd Quarter 2004.
ANTHONY PAYNE                                                                           PAGE TWO

CHESTERMAN COMPANY, Sioux City, IA                                                    1991 – 2001
Route Sales Professional
Sales and service of Coca-Cola branded products to accounts on assigned routes to maximize sales
revenue.
•      Demonstrated excellence in sales and service to clients resulting in a superior customer
       service rating during the 1997 Chesterman Company Customer Survey.
•      Utilized company authorized promotional pricing and developed an execution strategy
       resulting in a 2nd place rank in the 4th Quarter 1996, Sales Growth Contest with a 24%
       increase in total sales.
•      Developed an execution plan to convert 7up sales to Sprite sales, resulting in a 2nd place
       ranking during the 1995 Sprite Conversion Contest with a 108% conversion rate.


                                           EDUCATION

BS, Business Administration – Marketing, Wayne State College, Wayne, NE

                                PROFESSIONAL DEVELOPMENT

•   Reliant Pharmaceuticals Advanced Sales Training Graduate
•   The Essentials of Excellent Customer Service – SkillPath Seminars
•   Dale Carnegie Fast-Track Sales Training Course
•   Member of Chesterman Company Sales Training Team, 1995 – 2000
•   Member of Chesterman Company Safety Committee, 1995 – 2000

                           PHARMACEUTICAL INDUSTRY SPECIFIC

•   FDA Approvals: Rapaflo and Akten (Medscape CME), 2009
•   Prostate Cancer Screening and Prevention: A Clinical Update for Primary Care Providers
    (Medscape CME), 2008
•   Higher Nonfasting Triglycerides Linked With Increased Ischemic Stroke Risk (Medscape CME),
    2008
•   Omega-3 Rather Than Genetics Is Key to Lack of CHD in Japanese? (Medscape CME), 2008
•   Management of Benign Prostatic Hyperplasia Reviewed (Medscape CME), 2008
•   Emerging Data in the Treatment of Mixed Dyslipidemia (Medscape CME), 2008
•   Understanding Triglycerides: Beyond LDL Cholesterol (Medscape CME), 2007
•   New Analysis Uncovers Relationship Between Low LDL Cholesterol Levels and Cancer
    (Medscape CME), 2007
•   Nonfasting Triglyceride Levels Associated With an Increased Risk for Cardiovascular Disease
    (Medscape CME), 2007
•   Fish Oil Added to Statin Therapy Reduces Risk For Major Coronary Events (Medscape CME),
    2007
•   LDL-C -- How Low Should You Go? (Medscape CME), 2007
•   Fish Oil May Not Reduce Risk of Ventricular Tachycardia or Ventricular Fibrillation in Patients
    With an Implantable Cardioverter Defibrillator (Medscape CME), 2006
•   New Therapies and Multiple Targets: Moving Beyond Low-Density Lipoprotein Cholesterol in the
Management of Cardiovascular Risk (Medscape CME), 2005
ANTHONY PAYNE                                                                      PAGE THREE

PHARMACEUTICAL INDUSTRY SPECIFIC (Continued)
•   Rimonabant May Reduce Weight and Cardiovascular Risk Factors (Medscape CME), 2005
•   Stop the Progression: New Approaches to Early Aggressive Combination Therapy (Medscape
    CME), 2005
•   Rosuvastatin May Be More Closely Associated With Toxicity Than Are Other Statins (Medscape
    CME), 2005
•   Reliant Pharmaceuticals District Representative for Regional Scientific Committee, 2005
•   Good Morning Diabetes: Building a New Framework for Combination Therapy (Medscape CME),
    2004
•   Sculpting New Treatment Strategies for High-Risk Patients With Dyslipidemia (Medscape CME),
    2004
•   W.A.T.C.H.: Women's Agenda Targeting Cholesterol in Heart Disease (Medscape CME), 2004
•   NCEP Updates ATP III Guidelines With Evidence From Recent Statin Trials (Medscape CME),
    2004

Payne, Anthony Formatted Resume2

  • 1.
    ANTHONY PAYNE 607 Birchwood Court Jefferson, SD 57038 Home: 605.540.0442 matpayne@cableone.net Cell: 712.574.0216 SUMMARY Accomplished Sales Professional with proven ability to drive territorial growth. A self-motivated expeditor known for creating and implementing effective targeting strategies to maximize results with high value customers. Additional strengths in making consultative sales presentations, providing excellent customer service, and continued industry self education. PROFESSIONAL EXPERIENCE GLAXOSMITHKLINE, Research Triangle Park, NC 2008 – 2010 Pharmaceutical Sales Representative Promoted medications in a sales team environment to practicing physicians and mid-level providers within an assigned territory that ensured the appropriate use of products to achieve the business potential of the territory. • Ranked in the Top 10% Nationally for Lovaza 1st Quarter 2010 goal attainment by building relationships with medical providers and providing relevant information about the link between cardiovascular disease and product benefits. • Assigned to a dormant, under-performing territory in January 2009, developed and executed a sales strategy which transformed the territory to a ranking of Top 10% nationally in division portfolio attainment within a year. • First place rank regionally during the 4th Quarter of 2008 in Total Portfolio Achievement with a portfolio achievement of 257% of goal, executing on division plan of action in a newly developed territory after being retained by GlaxoSmithKline in April 2008. RELIANT PHARMACEUTICALS, Liberty Corner, NJ 2001 – 2008 Pharmaceutical Sales Representative Ethically promoted medications in a single member territory environment to practicing physicians and mid-level providers in a variety of assigned territories that ensured the appropriate use of promoted products to maximize profitability of the territories. • Developed and executed a plan of action that resulted in a 6th place rank nationally in Total Portfolio Achievement of the 90 sales professionals that were retained by GlaxoSmithKline after the purchase and merger of Reliant Pharmaceuticals. • Awarded additional territory in January 2007 that had been dormant for two years. Introduced Lovaza with a well defined and executed strategy that led to a Top 1% rank nationally in Total Prescription Growth in the Primary Care Division during the 4th Quarter over 3rd Quarter 2007 with 33.69% increase in sales. • Utilized national Dyna Circ CR branding strategy while incorporating personally customized execution of this strategy resulting in the Exceptional Sales Achievement in Hypertension Award in October 2006, and again in May 2007. • Followed regionally developed portfolio plan of action while maximizing features and benefits of portfolio products resulting in the Regional Sales Award for the 4th Quarter 2002 and again for the 2nd Quarter 2004.
  • 2.
    ANTHONY PAYNE PAGE TWO CHESTERMAN COMPANY, Sioux City, IA 1991 – 2001 Route Sales Professional Sales and service of Coca-Cola branded products to accounts on assigned routes to maximize sales revenue. • Demonstrated excellence in sales and service to clients resulting in a superior customer service rating during the 1997 Chesterman Company Customer Survey. • Utilized company authorized promotional pricing and developed an execution strategy resulting in a 2nd place rank in the 4th Quarter 1996, Sales Growth Contest with a 24% increase in total sales. • Developed an execution plan to convert 7up sales to Sprite sales, resulting in a 2nd place ranking during the 1995 Sprite Conversion Contest with a 108% conversion rate. EDUCATION BS, Business Administration – Marketing, Wayne State College, Wayne, NE PROFESSIONAL DEVELOPMENT • Reliant Pharmaceuticals Advanced Sales Training Graduate • The Essentials of Excellent Customer Service – SkillPath Seminars • Dale Carnegie Fast-Track Sales Training Course • Member of Chesterman Company Sales Training Team, 1995 – 2000 • Member of Chesterman Company Safety Committee, 1995 – 2000 PHARMACEUTICAL INDUSTRY SPECIFIC • FDA Approvals: Rapaflo and Akten (Medscape CME), 2009 • Prostate Cancer Screening and Prevention: A Clinical Update for Primary Care Providers (Medscape CME), 2008 • Higher Nonfasting Triglycerides Linked With Increased Ischemic Stroke Risk (Medscape CME), 2008 • Omega-3 Rather Than Genetics Is Key to Lack of CHD in Japanese? (Medscape CME), 2008 • Management of Benign Prostatic Hyperplasia Reviewed (Medscape CME), 2008 • Emerging Data in the Treatment of Mixed Dyslipidemia (Medscape CME), 2008 • Understanding Triglycerides: Beyond LDL Cholesterol (Medscape CME), 2007 • New Analysis Uncovers Relationship Between Low LDL Cholesterol Levels and Cancer (Medscape CME), 2007 • Nonfasting Triglyceride Levels Associated With an Increased Risk for Cardiovascular Disease (Medscape CME), 2007 • Fish Oil Added to Statin Therapy Reduces Risk For Major Coronary Events (Medscape CME), 2007 • LDL-C -- How Low Should You Go? (Medscape CME), 2007 • Fish Oil May Not Reduce Risk of Ventricular Tachycardia or Ventricular Fibrillation in Patients With an Implantable Cardioverter Defibrillator (Medscape CME), 2006 • New Therapies and Multiple Targets: Moving Beyond Low-Density Lipoprotein Cholesterol in the
  • 3.
    Management of CardiovascularRisk (Medscape CME), 2005
  • 4.
    ANTHONY PAYNE PAGE THREE PHARMACEUTICAL INDUSTRY SPECIFIC (Continued) • Rimonabant May Reduce Weight and Cardiovascular Risk Factors (Medscape CME), 2005 • Stop the Progression: New Approaches to Early Aggressive Combination Therapy (Medscape CME), 2005 • Rosuvastatin May Be More Closely Associated With Toxicity Than Are Other Statins (Medscape CME), 2005 • Reliant Pharmaceuticals District Representative for Regional Scientific Committee, 2005 • Good Morning Diabetes: Building a New Framework for Combination Therapy (Medscape CME), 2004 • Sculpting New Treatment Strategies for High-Risk Patients With Dyslipidemia (Medscape CME), 2004 • W.A.T.C.H.: Women's Agenda Targeting Cholesterol in Heart Disease (Medscape CME), 2004 • NCEP Updates ATP III Guidelines With Evidence From Recent Statin Trials (Medscape CME), 2004